Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06280950 · ClinicalTrials.gov registry record · Phase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
A Phase 2 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 8
- Study locations
NCT06280950 is a Phase 2 study of Liver Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 340 participants, below the 5,440-participant average among 19 other Liver Transplant trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06280950, a Phase 2 study of Liver Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Tacrolimus (continued reduction)
- DRUG Tacrolimus (maintain 50% reduction)
Study Locations (8)
Pennsylvania
- University of Pennsylvania (Site #: 71111) - Philadelphia
- University of Pittsburgh Medical Center (Site #: 71170) - Pittsburgh
Arizona
- Mayo Clinic Hospital Arizona (Site #: 71144) - Phoenix
California
- University of California, San Francisco (Site #: 71108) - San Francisco
Illinois
- Northwestern University (Site #: 71110) - Chicago
New York
- Icahn School of Medicine at Mount Sinai (Site #: 71115) - New York
North Carolina
- Duke University Medical Center (Site #: 71139) - Durham
Texas
- Baylor Medical Center (Site #: 71153) - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2024-09-12 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06280950
The ClinicalTrials.gov registry entry for NCT06280950 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,440-participant average among 19 other Liver Transplant trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 3 interventions - of which Everolimus is the first listed.
NCT06280950 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06280950 about?
NCT06280950 is a clinical study titled "Expanding Liver Transplant Immunosuppression Minimization Via Everolimus". This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of tw...
What is the current status of trial NCT06280950?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2024-09-12. Estimated completion is 2029-06-01.
What conditions does trial NCT06280950 study?
This clinical trial studies the following conditions: Liver Transplant.
What interventions are being tested in trial NCT06280950?
The interventions under investigation include: Everolimus (DRUG), Tacrolimus (continued reduction) (DRUG), Tacrolimus (maintain 50% reduction) (DRUG).
Who is sponsoring clinical trial NCT06280950?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06280950 being conducted?
This trial has 8 study locations across Arizona, California, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
RECRUITING · Phase 2
-
Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue
RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
COMPLETED · Phase 2
-
US National OCS Liver Perfusion (OLP) Registry
RECRUITING
-
Liver Transplant CGM
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.